Please list at least 3 keywords which relate to your manuscript::second generation antipsychotics, depressive episode, bipolar disorder, placebo, meta-analysis Abstract:Depressive symptoms and episodes dominate the course of bipolar disorder. However, the therapeutic armamentarium for bipolar depression is limited. Recent evidence points at the efficacy of second generation antipsychotics (SGAs) for the treatment of bipolar depression. We conducted a systematic review and meta-analysis of the efficacy and safety of SGAs (randomized, double-blind, placebocontrolled trials; used in monotherapy) in the treatment of adult patients with bipolar depression. Publication bias was corrected for by performing similar searches using the clinical trials register of the respective pharmaceutical companies, the Cochrane database and ClinicalTrials.gov. Seven published papers were identified on the use of aripiprazole, olanzapine and quetiapine. Disclaimer:Funding for this meta-analysis was provided by AstraZeneca Belgium. AstraZeneca Belgium had no role in study design; in the collection, analysis and interpretation of the data; and in the decision to submit the paper for publication. Corresponding author:Jürgen 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59

No abstract

No abstract

No abstract

In this work the organization of the hemovigilance system in France, the alert system related to undesirable transfusion effects and the search for seropositive blood donors is discussed. Rev.bras.hematol.hemoter., 2000(22) (3): 368-373